Schedule of Events

Individual presenter disclosures will be linked to their names in the Schedule of Events below. You will also be able to view all presenter disclosures at once.

[M] = medical oncologist, [R] = radiation oncologist, [S] = surgeon/surgical oncologist


Wednesday, March 13, 2019

4:00 p.m. - 6:00 p.m.
Registration

Thursday, March 14, 2019

7:00 a.m. - 5:00 p.m.
Registration

7:00 a.m. - 8:00 a.m.
Continental Breakfast

7:50 a.m. - 8:00 a.m.
Day One Welcome
Jessica S. Donington, MD, New York University Cancer Center, New York [S]

8:00 a.m. - 9:15 a.m.
General Session I: Lung Cancer Screening and Diagnosis
Moderator: Lecia V. Sequist, MD, MPH, Massachusetts General Hospital, Boston [M]

  • Why Has Screening Not Been More Widely Adopted?
    Renda Soylemez Wiener, MD MPH, Boston University, Boston [Pulmonologist]
  • Radiomics and Radiogenomics in Lung Cancer Diagnosis
    Ann Leung, MD, Stanford University Medical Center, Stanford, California [Radiologist]
  • Advanced Bronchoscopic and Targeting Techniques for Diagnosis
    Jamie L. Bessich, MD, NYU Langone Laura and Isaac Perlmutter Cancer Center, New York [S]
  • Early Detection Using Blood and Breath Biomarkers
    Peter Mazzone, MD, MPH, Cleveland Clinic, Cleveland [Pulmonologist] 
  • Questions and Answers
9:15 a.m. - 9:30 a.m.
Break

9:30 a.m. - 10:15 a.m.
Keynote I: Updates from the National Lung Cancer Round Table
Moderator: Ramesh Rengan, MD, PhD, University of Washington, Seattle [R]
Speaker: Ella A. Kazerooni, MD, University of Michigan, Ann Arbor, Michigan [Diagnostic Radiologist]

10:15 a.m. - 10:45 a.m.
Coffee Break

10:45 a.m. - 12:15 p.m.
Plenary Session
Moderator: Sue Yom, MD, PhD, University of California, San Francisco [R]

  • 1: Improved Overall Survival with Local Consolidative Therapy in Oligometastatic Non-small Cell Lung Cancer: Results from a Cohort of 194 Patients with Synchronous Disease
    Kyle Mitchell, MD, MD Anderson Cancer Center, Houston
  • 2: Upstaging in Repeat PET/CT prior to Chemoradiation in Locally Advanced NSCLC: Implications for Clinical Care
    Jing Zeng, MD, University of Washington, Seattle
  • 3: The Impact of the Stage III Randomized Trial by Takahashi et al. on the Use of Prophylactic Cranial Irradiation (PCI) in Patients with Extensive-stage Small Cell Lung Cancer (ES-SCLC)
    Olsi Gjyshi, MD, PhD, MD Anderson Center, Houston
  • Discussant
    TBD
  • 4: Tumor Treating Fields Plus Chemotherapy for First-line Treatment of Malignant Pleural Mesothelioma: Final Results of the STELLAR Trial
    Giovanni Ceresoli, MD, Istituto Clinico Humanitas IRCCS, Rozzano, Italy
  • 5: The Impact of Structured, Prospective Exposure to the NCCN Guidelines when Making Treatment Decisions: Improved Metrics of Guideline-Concordant Care for Patients with Non-small Cell Lung Cancer
    Susan Wu, MD, University of California, San Francisco
  • 6: Multidisciplinary Treatment of Thymic Neuroendocrine Tumors: Evaluation of the Impact of Surgery, Chemotherapy, and Radiation
    Erin Corsini, MD, MD Anderson Cancer Center, Houston
  • 7: Correlation of Survival Outcomes with Clinical and Molecular features in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
    Ruqin Chen, MB, Mayo Clinic Florida, Jacksonville, Florida
  • Discussant

12:15 p.m. - 1:15 p.m.
Lunch in the Exhibit Hall
Expert Office Hours

1:15 p.m. - 2:45 p.m.
General Session II: Early Stage Thoracic Cancers
Moderator: Jessica S. Donington, MD, New York University Cancer Center, New York [S]

  • Surgical Options for Stage I NSCLC, Including Synchronous and Metachronous Primaries: Pros and Cons
    Melanie Edwards, MD, St. Joseph Mercy/IHA Thoracic Surgery, Ypsilanti, Michigan [S]
  • Radiation Therapy Including SBRT for Stage I NSCLC – Pros and Cons
    Jing Zeng, MD, University of Washington, Seattle [R]
  • The Medical Oncologist and Stage I NSCLC: Is There a Role for Adjuvant and/or Neoadjuvant Therapy?
    Hatim Husain, MD, University of California San Diego, La Jolla, California [M]
  • Early Stage Tumor Board
  • Questions and Answers
2:45 p.m. - 3:15 p.m.
Coffee Break

3:15 p.m. - 5:00 p.m.
General Session III: Locally Advanced Stage III Cancer
Moderator: Ramesh Rengan, MD, PhD, University of Washington, Seattle [R]
  • Systemic Therapy: Induction, Consolidation, Immunotherapy
    Jyoti Patel, MD, University of Chicago [M]
  • Does Surgery Have a Role in Stage III NSCLC?
    Mark W. Onaitis, MD, UC San Diego Health, La Jolla, California [S]
  • Neoadjuvant or Adjuvant Radiotherapy for Stage III NSCLC?
    Cecile Le Péchoux, MD, Institut de Cancérologie Gustave Roussy, Villejuif, France [R]
  • Definitive Chemoradiotherapy in Stage III NSCLC
    Arya Amini, MD, City of Hope, Duarte, California [R]
  • Locally Advanced Tumor Board
    • Additional panelist: Peter Mazzone, MD, MPH, Cleveland Clinic, Cleveland [Pulmonologist]
  • Q&A/Discussion
5:00 p.m. - 6:00 p.m.
Poster Viewing Session and Reception

Friday, March 15, 2019

7:00 a.m. - 4:30 p.m.
Registration

7:00 a.m. - 8:00 a.m.
Continental Breakfast

7:55 a.m. - 8:00 a.m.
Day Two Welcome
Nathan A. Pennell, MD, PhD, Cleveland Clinic, Cleveland [M]

8:00 a.m. - 9:15 a.m.
General Session IV: Evaluation, Prehabilitation, ERAS, and Quality of Life
Moderator: Richard Whyte, MD, Beth Israel Deaconess Medical Center, Boston [S]

  • Frailty, Resiliency, and Treatment Decisions
    Mark K. Ferguson, MD, University of Chicago, Chicago [S]
  • ERAS in Lung Resection: What Non-surgeons Need To Know
    Linda W. Martin, MD, MPH, FACS, FCCP, University of Virginia Health System, Charlottesville, Virginia [S]
  • Patient Reported Outcomes for NSCLC Therapy
    Benjamin Movsas, MD, Henry Ford Health System, Detroit [R]
  • Supportive and End-of-Life Care
    Lauren Hertan, MD, MS, Beth Israel Deaconess Medical Center, Boston [Supportive Care Expert]
  • Questions and Answers
9:15 a.m. - 9:30 a.m.
Break

9:30 a.m. - 10:15 a.m.
Keynote II: Opioid Use and Cancer Patients’ Pain Management
Moderator: Ravi Salgia, MD, PhD, City of Hope, Duarte, California [M]
Speaker: Eduardo Bruera, MD, FAAHPM, MD Anderson Cancer Center, Houston [M]

10:15 a.m. - 10:45 a.m.
Coffee Break

10:45 a.m. - 12:15 p.m.
Oral Abstract Session
Moderator: Melanie Edwards, MD, St. Joseph Mercy/IHA Thoracic Surgery, Ypsilanti, Michigan [S]
 
  • 8: Stereotactic Ablative Radiotherapy (SABR) in Early Stage Non-Small Cell Lung Cancer: A National Cancer Database (NCDB) Propensity Matched Analysis Comparing Survival in Adenocarcinoma and Squamous Cell Carcinoma
    Stephen Abel, DO, Allegheny Health Network Cancer Institute, Pittsburgh
  • 9: Impact of Operability and Minimally Invasive Techniques on Post-Treatment Mortality with SBRT and Surgery in Early Stage NSCLC
    William Stokes, MD, Emory University, Atlanta
  • 10: Stereotactic Body Radiotherapy versus Local Tumor Ablation for Early-Stage Non-Small Cell Lung Cancer
    Bryan Ager, MD, University of Utah, Salt Lake City
  • 11: Outcomes after lung stereotactic body radiotherapy with and without pathologic confirmation
    Joel Wilkie, MD, PhD, University of Michigan, Ann Arbor, Michigan
  • 12: Early Outcomes of Patients with Locally-Advanced Non-small Cell Lung Cancer Treated with Intensity-Modulated Proton vs. Intensity-Modulated Radiation Therapies: A Single-Institution Experience
    Nathan Yu, MD, Mayo Clinic, Phoenix
  • 13: Treatment Allocation Modeling and Risk-Stratified Outcomes for Clinical Stage I Non-small Cell Lung Cancer Patients Receiving Surgery versus Stereotactic Body Radiation Therapy
    Pamela Samson, MD, Washington University, St. Louis
  • 14: Local therapy for oligoprogression in NSCLC patients being treated with osimertinib
    Chunyu Wang, MD, Memorial Sloan Kettering Cancer Center, New York
  • Discussant
    TBD

12:15 p.m. - 1:15 p.m.
Lunch in the Exhibit Hall
Trainee and Early-career Networking Luncheon

Speakers:
  • Ravi Salgia, MD, PhD, City of Hope, Duarte, California [M]
  • Linda W. Martin, MD, MPH, FACS, FCCP, University of Virginia Health System, Charlottesville, Virginia [S]
  • Sue Yom, MD, PhD, University of California, San Francisco [R]

1:15 p.m. - 2:15 p.m.
General Session V: Rare Thoracic Cancers
Moderator: Aaron S. Mansfield, MD, Mayo Clinic, Rochester, Minnesota [M]

  • Mesothelioma
    Shirish M. Gadgeel, MD, University of Michigan, Ann Arbor, Michigan [M]
  • Thymic Epithelial Tumors
    Heather Wakelee, MD, Stanford University, Stanford, California [S]
  • Novel Imaging and Treatments in Neuroendocrine Tumors
    Andrei H. Iagaru, MD, Stanford School of Medicine, Stanford, California [Nuclear Medicine Physician]
  • Questions and Answers

2:15 p.m. - 2:45 p.m.
Coffee Break

2:45 p.m. - 4:30 p.m.
General Session VI: Advanced Non-small Cell Lung Cancer
Moderator: Shirish M. Gadgeel, MD, University of Michigan, Ann Arbor, Michigan [M]
  • Integrating Chemotherapy and Immune Therapy
    Thomas Eldridge Stinchcombe, MD, Duke Cancer Institute, Durham, North Carolina [M]
  • Current State-of-the-Art for EGFR+ and ALK+ Patients
    Heather Wakelee, MD, Stanford University, Stanford, California [M]
  • Emerging Targeted Therapies
    Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center, New York [M]
  • Oligometastatic Disease – Treatment Options
    Daniel R. Gomez, MD, MD Anderson Cancer Center, Houston [R]
  • Advanced Non-small Cell Lung Cancer Tumor Board
  • Questions and Answers 

Saturday, March 16, 2019

7:00 a.m. - 12:00 p.m.
Registration

7:00 a.m. - 8:00 a.m.
Continental Breakfast

7:55 a.m. - 8:00 a.m.
Day Three Welcome
Ramesh Rengan, MD, PhD, University of Washington, Seattle [R]

8:00 a.m. - 9:00 a.m.
General Session VII: What’s New in Small Cell Lung Cancer?
Moderator: Ravi Salgia, MD, PhD, City of Hope, Duarte, California [M]

  • Current Radiation Management of Small Cell
    Jeffrey A. Bogart, MD, State University of New York, New York [R]
  • Current Medical Management of Small Cell
    Ticiana A. Leal, MD, University of Wisconsin, Madison, Wisconsin [M]
  • Emerging Approaches
    Helen J. Ross, MD, Mayo Clinic, Scottsdale, Arizona [M]
  • Questions and Answers
9:00 a.m. - 9:15 a.m.
Break

9:15 a.m. - 10:45 a.m.
General Session VIII: Special Topics in Immunotherapy
Moderator: Sue Yom, MD, PhD, University of California, San Francisco [R]
  • Radiation and Immunotherapy: The Inflammation Perfect Storm
    Sean Park, MD, MS, PhD, Mayo Clinic, Rochester, Minnesota [R]
  • Immunotherapy and Brain Metastases
    Sarah B. Goldberg, MD, MPH, Yale Cancer Center, New Haven, Connecticut [M]
  • Hyperprogression in Patients on Immunotherapy
    Christophe Le Tourneau, MD, PhD, Institut Curie, Paris [M]
  • Immunotherapy Tumor Board
  • Q&A/Discussion

10:45 a.m. - 11:00 a.m.
Break

11:00 a.m. - 12:00 p.m.
General Session IX: Management of Immunotherapy Toxicities
Moderator: Nathan A. Pennell, MD, PhD, Cleveland Clinic, Cleveland [M]
  • Pulmonary Toxicities of Chemotherapy and Immunotherapy for NSCLC
    M. Patricia Rivera, MD, UNC School of Medicine, Chapel Hill, North Carolina [Pulmonologist]
  • Safety of Immunotherapy in Patients with Autoimmune Disease
    Martin J. Edelman, MD, Fox Chase Cancer Center, Philadelphia [M]
  • Toxicities of Immunotherapy Combined with Targeted Therapies
    Leora Horn, MD, MSc, Vanderbilt University, Nashville, Tennessee [M]
  • Questions and Answers
Copyright © 2018 American Society for Radiation Oncology | Conflict of Interest | Terms of Use | Privacy Policy | Contact Us 
251 18th Street South, 8th Floor, Arlington, VA 22202 | Phone: 703.502.1550 | Fax: 703.502.7852